Enanta Pharmaceuticals Inc (ENTA) Insider Continues To Decrease Holdings In The Company


Enanta Pharmaceuticals Inc (NASDAQ: ENTA), saw it’s Chief Scientific Officer Sun Yat Or dispose of 5,000 combined shares of common stock. This trade was completed in two transactions, the first saw Or drop 4,700 shares at a range of $41.83 to $42.64 per share; the other one was for a sale of 300 shares at a range of $42.84 to $43.2 per share.

This was not Or’s first time selling stock in Enanta Pharmaceuticals Inc (NASDAQ: ENTA), the $792.49 million market cap biotechnology company. Or has lowered his holdings by over 20,000 shares since the beginning of April this year.

In addition, there are two major hedge funds with holdings in the company. Peter Kolchinsky‘s Ra Capital Management remained steady, showing no movement last quarter, and now holds 1,541,078 shares worth about $61.6 million; Mitchell Blutt‘s Consonance Capital Management increased it’s position by 47% last quarter, now with 1,254,459 shares in Enanta Pharmaceuticals Inc (NASDAQ: ENTA), worth about $50 million.

Disclosure: The author, Daniel Forstein, holds no positions in any stocks mentioned.